Impact of OSA on biological markers in morbid obesity and metabolic syndrome

Journal of Clinical Sleep Medicine

Volumn 10, Issue 3, 2014, Pages 263-270

  Salord, Neus ^a,b,c,d   Gasa, Mercè ^a,b   Mayos, Mercedes ^c,d,e   Fortuna Gutierrez, Ana Maria ^d,e   Montserrat, Josep Maria ^d,f   Sánchez de la Torre, Manuel ^d,g   Barceló, Antonia ^d,h   Barbé, Ferran ^d,h   Vilarrasa, Núria ^a,i   Monasterio, Carmen ^a,b,d  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

^h HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

ⁱ INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Adipokines; Endothelial dysfunction; Inflammatory markers; Metabolic syndrome; Obesity; Obstructive sleep apnoea

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; BIOLOGICAL MARKER; CD40 LIGAND; CHEMERIN; INTERLEUKIN 6; LEPTIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN; CHEMERIN, HUMAN; CHEMOKINE; VASCULOTROPIN A;

ADULT; APNEA HYPOPNEA INDEX; ARTICLE; ATHEROSCLEROSIS; BODY MASS; BODY WEIGHT; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; FEMALE; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MORBID OBESITY; NECK CIRCUMFERENCE; OBSERVATIONAL STUDY; POLYSOMNOGRAPHY; SLEEP DISORDERED BREATHING; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; WAIST HIP RATIO; BLOOD; CASE CONTROL STUDY; COMPLICATION;

ADIPONECTIN; ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CD40 LIGAND; CHEMOKINES; FEMALE; HUMANS; INTERLEUKIN-6; LEPTIN; MALE; METABOLIC SYNDROME X; OBESITY, MORBID; SLEEP APNEA, OBSTRUCTIVE; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84897133119     PISSN: 15509389     EISSN: 15509397     Source Type: Journal    
DOI: 10.5664/jcsm.3524     Document Type: Article

References (41)

1. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International association for the Study of Obesity. Circulation 2009;120:1640-5.
2. Ford ES. Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care 2005;28:1769-78. (Pubitemid 40923091)
3. Lam JC, Mak JC, Ip MS. Obesity, obstructive sleep apnoea and metabolic syndrome. Respirology 2012;17:223-36.
4. Gasa M, Salord N, Fortuna AM, et al. Obstructive sleep apnea and metabolic impairment in severe obesity. Eur Respir J 2011;38:1089-97.
5. Arnardottir ES, Mackiewick M, Gislason T, Teff KL, Pack A. Molecular signatures of obstructive sleep apnea in adults: A review and perspective. Sleep 2009;32:447-70.
6. Bonsignore MR, McNicholas WT, Montserrat JM, Eckel J. Adipose tissue in obesity and obstructive sleep apnoea. Eur Respir J 2012;39:746-67.
7. Ernst MC, Sinal CJ. Chemerin. at the crossroads of inflammation and obesity. Trends Endocrinol Metab 2010;21:660-7.
8. Rosito GA, Massaro JM, Hoffmann U, et al. Pericardial fat, visceral abdominal fat, cardiovascular disease risk factors, and vascular calcification in a community-based sample: the Framingham Heart Study. Circulation 2008;117:605-13.
9. Duren DL, Sherwood RJ, Czerwinski SA, et al. Body composition methods: comparisons and interpretation. J Diabetes Sci Technol 2008;2:1139-46.
10. Pascot A, Després JP, Lemieux I, et al. Contribution of visceral obesity to the deterioration of the metabolic risk profile in men with impaired glucose tolerance. Diabetologia 2000;43:1126-35.
11. Barceló A, Piérola J, de la Peña M, et al. Free fatty acids and the metabolic syndrome in patients with obstructive sleep apnoea. Eur Respir J 2011;37:1418-23.
12. Trombetta IC, Somers VK, Maki-Nunes C, et al. Consequences of comorbid sleep apnea in the metabolic syndrome implications for cardiovascular risk. Sleep 2010;33:1193-9.
13. Kono M, Tatsumi K, Saibara T, et al. Obstructive sleep apnea syndrome is associated with some components of metabolic syndrome. Chest 2007;131:1387-92. (Pubitemid 46762343)
14. Lui MM, Lam JC, Mak HK, et al. C-reactive protein is associated with obstructive sleep apnea independent of visceral obesity. Chest 2009;135:950-6.
15. Karelis AD, Faraj M, Bastard JP, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab 2005;90:4145-50. (Pubitemid 41058189)
16. Aguilar-Salinas CA, García EG, Robles L, et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab 2008;93:4075-9.
17. Karelis AD, St-Pierre DH, Conus F, Rabasa-Lhoret R, Poehlman ET. Metabolic and body composition factors in subgroups of obesity: what do we know? J Clin Endocrinol Metab 2004;89:2569-75. (Pubitemid 38766333)
18. Soverini V, Moscatiello S, Villanova N, Ragni E, Di Domizio S, Marchesini G. Metabolic syndrome and insulin resistance in subjects with morbid obesity. Obes Surg 2010;20:295-301.
19. Frohlich M, Imhof A, Berg G, et al. Association between C-reactive protein and features of the metabolic syndrome a population-based study. Diabetes Care 2000;23:1835-9.
20. Ridker PM, Coo N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation 2004;109:1955-9. (Pubitemid 38544485)
21. Minoguchi, K. Yokoe T, Tazaki T, et al. Increased carotid intima media thickness and serum inflammatory markers in obstructive sleep apnea. Am J Respir Crit Care Med 2005;172:625-30.
22. Can M, Açikgöz S, Mungan G, et al Serum cardiovascular risk factors in obstructive sleep apnea. Chest 2006,129:233-7. (Pubitemid 43289839)
23. Ryan S, Nolan GM, Hannigan E, Cunningham S, Taylor C. McNycolas WT. Cardiovascular risk markers in obstructive sleep apnea syndrome and correlation with obesity. Thorax 2007;62:509-14. (Pubitemid 46910129)
24. Taheri S, Austin D, Lin L, Nieto F J, Young T, Mignot E. Correlates of serum C-reactive protein (CRP) - no association with sleep duration or sleep disordered breathing. Sleep 2007;30:991-6. (Pubitemid 47221899)
25. Korner J, Leibel RL. To eat or not to eat - how the gut talks to the brain. N Engl J Med 2003;349:926-8. (Pubitemid 37064764)
26. Galletiti F, Barbato A, Vesiero M, et al. Circulating Leptin levels predict the development of metabolic syndrome in middle-aged men: An 8-year follow-up study. J Hypertens 2007;25:1671-7. (Pubitemid 47056575)
27. Vogontzas AN, Papanicolaou DA, Bixler EO, et al. Sleep apnea and daytime sleepiness and fatigue: relation to visceral obesity, insulin resistance and hypercytokinemia. J Clin Endocrinol Metab 2000;85:1151-8. (Pubitemid 32269364)
28. Fantuzzi G. Molecular mechanisms in allergy and clinical immunology. J Allergy Clin Immunol 2005;115:911-9.
29. Wolk R, Svatikova A, Nelson CA, et al. Plasma levels of adiponectin, a novel adipocyte-derived hormone, in sleep apnea. Obes Res 2005;13:186-90.
30. Makino S, Handa H, Suzukawa K, et al. Obstructive sleep apnea syndrome, plasma adiponectin levels and insulin resistance. Clin Edocrinol (Oxf) 2006;64:12-9.
31. Weigert J, Neumeier M, Wanninger J, et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 2010;72:342-8.
32. Feng X, Li P, Zhou C, Jia X, Kang J. Elevated levels of serum chemerin in patients with obstructive sleep apnea syndrome. Biomarkers 2012;17:248-53.
33. Kohler M, Stradling JR. Mechanisms of vascular damage in obstructive sleep apnea. Nat Rev Cardiol 2010;7:677-85.
34. Cherniack EP. Vascular endothelial growth factor and sleep apnea: clutching at straws in the night. Respiration 2007;74:17-8. (Pubitemid 46012443)
35. De la Peña M, Barceló A, Barbe F, et al. Endothelial function and circulating endothelial progenitor cells in patients with sleep apnea syndrome. Respiration 2008;76:28-32. (Pubitemid 351914136)
36. Imagawa S, Yamaguchi Y, Higuchi M, et al. Levels of vascular endothelial growth factor are elevated in patients with obstructive sleep apnea-hypopnea syndrome. Blood 2001;98:1255-7.
37. Szmitko PE, Wang CH, Weisel RD, Jeffries GA, Anderson TJ, Verma S. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation 2003;108:2041-8. (Pubitemid 37337575)
38. Drager LF, Bortolotto LA, Figueiredo AC, Krieger EM, Lorenzi GF. Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. Am J Respir Crit Care Med 2007;176:706-12. (Pubitemid 47503079)
39. Kohler M, Stoewhas AC, Ayers L, Senn O, et al. Effects of continuous positive airway pressure therapy withdrawal in patients with obstructive sleep apnea: a randomized controlled trial. Am J Respir Crit Care Med 2011;184:92-9.
40. Hoyos CM, Killick R, Yee BJ, Phillips CL, Grunstein RR, Liu PY. Cardiometabolic changes after continuous positive airway pressure for obstructive sleep apnoea: a randomised sham-controlled study. Thorax 2012;67:1081-9.
41. West SD, Nicoll DJ, Wallace TM, Matthews DR, Stradling JR. Effect of CPAP on insulin resistance and HbA1c in men with obstructive sleep apnoea and type 2 diabetes. Thorax 2007;62:969-74. (Pubitemid 350084496)